The timeline of neuronal and glial alterations in experimental obesity
Copyright © 2022 Elsevier Ltd. All rights reserved..
In experimental models, hypothalamic dysfunction is a key component of the pathophysiology of diet-induced obesity. Early after the introduction of a high-fat diet, neurons, microglia, astrocytes and tanycytes of the mediobasal hypothalamus undergo structural and functional changes that impact caloric intake, energy expenditure and systemic glucose tolerance. Inflammation has emerged as a central component of this response, and as in other inflammatory conditions, there is a time course of events that determine the fate of distinct cells involved in the central regulation of whole-body energy homeostasis. Here, we review the work that identified key mechanisms, cellular players and temporal features of diet-induced hypothalamic abnormalities. This article is part of the special Issue on 'Cross Talk between Periphery and the Brain'.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:208 |
|---|---|
| Enthalten in: |
Neuropharmacology - 208(2022) vom: 01. Mai, Seite 108983 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Engel, Daiane F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Astrocyte |
|---|
| Anmerkungen: |
Date Completed 14.04.2022 Date Revised 14.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neuropharm.2022.108983 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336760566 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336760566 | ||
| 003 | DE-627 | ||
| 005 | 20231225232856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuropharm.2022.108983 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336760566 | ||
| 035 | |a (NLM)35143850 | ||
| 035 | |a (PII)S0028-3908(22)00042-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Engel, Daiane F |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The timeline of neuronal and glial alterations in experimental obesity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2022 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a In experimental models, hypothalamic dysfunction is a key component of the pathophysiology of diet-induced obesity. Early after the introduction of a high-fat diet, neurons, microglia, astrocytes and tanycytes of the mediobasal hypothalamus undergo structural and functional changes that impact caloric intake, energy expenditure and systemic glucose tolerance. Inflammation has emerged as a central component of this response, and as in other inflammatory conditions, there is a time course of events that determine the fate of distinct cells involved in the central regulation of whole-body energy homeostasis. Here, we review the work that identified key mechanisms, cellular players and temporal features of diet-induced hypothalamic abnormalities. This article is part of the special Issue on 'Cross Talk between Periphery and the Brain' | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Astrocyte | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Microglia | |
| 650 | 4 | |a Proopiomelanocortin | |
| 650 | 4 | |a Tanycyte | |
| 700 | 1 | |a Velloso, Licio A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuropharmacology |d 1970 |g 208(2022) vom: 01. Mai, Seite 108983 |w (DE-627)NLM000008486 |x 1873-7064 |7 nnns |
| 773 | 1 | 8 | |g volume:208 |g year:2022 |g day:01 |g month:05 |g pages:108983 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuropharm.2022.108983 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 208 |j 2022 |b 01 |c 05 |h 108983 | ||